Clinical Trials

Pfizer Announces COVID-19 Antiviral Pill

Last Friday, Pfizer announced that the clinical trial for their COVID-19 antiviral pill, Paxlovid, demonstrated high efficacy in preventing severe COVID-19 in at-risk persons. Paxlovid is unique and differs from Merck’s COVID-19 antiviral, Molnupiravir, by binding to enzymes responsible for the replication of SARS-CoV-2 and inhibiting its life cycle.

Read More »

Merck Submits COVID Antiviral Pill for EUA

This morning, the pharmaceutical company Merck submitted an application for EUA of their COVID-19 oral antiviral pill. If accepted, this will become the first pill authorized by the FDA to treat COVID-19. Other FDA authorized COVID-19 treatments must be administered intravenously or via injection.

Read More »